Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia.
10.7534/j.issn.1009-2137.2014.04.032
- Author:
Qun SHAO
1
;
Zhi-Dong WANG
2
;
Xiao-Li ZHENG
2
;
Lei DONG
2
;
Dong-Mei HAN
2
;
Hong-Ming YAN
2
;
Heng-Xiang WANG
2
;
Lian-Ning DUAN
3
Author Information
1. Department of Hematology, Clinical College of Chinese Air Force, Anhui Medical University, Beijing 100142.
2. Department of Hematology, Chinese Air Force General Hospital, Beijing 100142, China.
3. Department of Hematology, Clinical College of Chinese Air Force, Anhui Medical University, Beijing 100142. E-mail: duanlianning@hotmail.com.
- Publication Type:Journal Article
- MeSH:
Adult;
Child, Preschool;
Hematopoietic Stem Cell Transplantation;
Humans;
Infant;
Leukemia, Myelomonocytic, Chronic;
therapy;
Leukemia, Myelomonocytic, Juvenile;
therapy;
Male;
Middle Aged;
Transplantation, Homologous;
Treatment Outcome
- From:
Journal of Experimental Hematology
2014;22(4):1058-1062
- CountryChina
- Language:Chinese
-
Abstract:
This study was purposed to explore the therapeutic efficacy and influencing factors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with chronic myelomonocytic leukemia (CMML) and in patients with juvenile myelomonocytic leukemia (JMML). The clinical data of 3 cases of CMML and 2 cases of JMML underwent allo-HSCT were analysed in term of multiparameter. The results showed that the hematopoietic stem cells in 5 patients grafted successfully. One case of JMML died of pulmonary disease, other 4 cases survive without disease. The analysis found that the disease burden before transplant, chromosome karyotype, acute GVHD II-IV and poor risk cytogenetics all associated with the relapse rate and disease-free survival rate of CMML. The low intensity conditioning regimen was better than myeloablative conditioning regimen. Type of donor and source of stem cells did not statistically and significantly affect OS and RFS. The splenectomy before allo-HSCT as well as spleen size at time of the alloHSCT did not influence on posttransplantation outcome of JMML. However, cord blood HSCT for JMML patients delayed hematologic recovery as compared to that of bone marrow or peripheral blood HSCT. The age, GVHD, HbF level played an important role in leukemia replace. It is concluded that the allogeneic hematopoietic stem cell transplantation is a curative regimen for CMML and JMML, but there also is a serial problems to be resolved.
